Malignant Solid Neoplasm — Trials

Malignant Solid Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 429
Recruiting: 209
Ph III recruiting: 10
Growth YoY: +2.3%
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (101)

clinicaltrialsPublishedShowing 251–252 of 252 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00516438	Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan	completed	Phase 1	48	AstraZenecaINDUSTRY	1	Dec 8, 2010	clinicaltrials
NCT00478101	Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain	completed	Phase 2	2,006	Gachon University Gil Medical CenterOTHER	0	Mar 13, 2008	clinicaltrials